Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 32Tumor-Agnostic 1Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Neoplasm Metastasis 1

Interventions

pembrolizumab 25Specimen Handling 17Blood Specimen Collection 17Biopsy 16Magnetic Resonance Spectroscopy 15atezolizumab 11Surveys and Questionnaires 11Bevacizumab 9Radiotherapy 8Radiosurgery 8Nivolumab 8Fluorouracil 8Standard of Care 7Paclitaxel 7Irinotecan 7Gemcitabine 7Cisplatin 7olaparib 6durvalumab 6Palliative Care 6Oxaliplatin 6Leucovorin 6Cyclophosphamide 6Carboplatin 6Capecitabine 6alectinib 5abemaciclib 5Trastuzumab 5Interviews as Topic 5Exercise 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × enfortumab vedotin × Tumor-Agnostic × Clear all
NCT06311214 2026-05-27

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
500 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡